Drug-based intervention on cardiovascular disease is currently based on risk factor control. However, none of these interventions can be considered specific to cardiovascular disease. In addition, the prediction of cardiovascular disease development, progression, and complications (i.e. plaque rupture) is still a difficult challenge and thus efforts towards targeted therapies remain limited.
SysVASC is focused on multidisciplinary research integrating leading experts in Europe to understand and model biological processes in vascular damage. SysVASC aims to show-case the application of systems biology in clinical research and development. Collectively, SysVASC's holistic approach, integrating massive molecular, clinical, pathological data in combination with novel systems biology approaches, will enable the detection of key molecular pathology of cardiovascular disease and pave the way for individualized risk prediction and targeted therapy.
It is also foreseen that the mathematical tools and experience gained from this project will be applicable to the investigation of multiple diseases, since the principal challenge, the identification of relevant targets and the availability of appropriate models systems, is relevant for common chronic diseases.
SysVASC provides an ambitious framework towards a true system’s medicine approach. The collaboration of basic scientists with renowned clinical centres will ease translation of the findings, which is further supported by the industry partners, poised to exploit project outcomes. This is further aided by established relationships with pharmaceutical companies as well as regulatory bodies. As such, an excellent framework exists which will support effective translation of research outcomes into application, and ultimately products that meet an urgent clinical need and support the competitiveness of European research intensive SMEs in a global market.
Although the project has only just begun, the SysVASC consortium begins the project with the commitment to publicize the impact of the project as results become available. Therefore, this section will be regularly updated to include the impact of the project in the following categories: modelling, therapeutic targets, in vivo models, and technology transfer during the lifetime of the project.
Further details will be added in the course of the project.